Medicinal Chemistry for Drug Discovery: Significance of Recent Trends

Table of Contents

Chapter 1 INTRODUCTION

• 1.1. Background
• 1.2. Scope and Nature of the Report

Chapter 2 EVOLUTION OF ORGANIC AND MEDICINAL CHEMISTRY IN PHARMA

• 2.1. Pharmaceutical Trends over Time
• 2.2. Combinatorial Chemistry
• 2.3. Lipinski' s Rule of Five
• 2.4. Impact of Lipinski' s Rule of Five

Chapter 3 ORGANIC AND MEDICINAL CHEMISTRY TECHNOLOGIES FOR DRUG DISCOVERY

• 3.1. Computer-Aided Drug Design
  • Virtual Screening
  • Target Structure-Based Design
  • Ligand Structure-Based Design
  • De Novo Compound Design
  • QSAR (Quantitative Structure-Activity Relationship)
  • Fragment-Based Drug Design
• 3.2. Diversity-Oriented Synthesis in Drug Design
• 3.3. Natural Products-Based Drug Design
• 3.4. Chemogenomics and Drug Design
• 3.5. Perspectives

Chapter 4 APPLICATIONS OF ORGANIC AND MEDICINAL CHEMISTRY IN DRUG DISCOVERY

• 4.1. Overview of Technology Approaches of Outsourcing Vendors
• 4.2. Overview of Service Offerings by Drug Discovery Outsourcing Vendors
• 4.3. Structure-Based Drug Design
• 4.4. Fragment-Based Drug Design
• 4.5. Natural Products-Based Drug Discovery
• 4.6. Diversity-Oriented Synthesis in Drug Discovery
• 4.7. Virtual Screening

Chapter 5 MARKET DYNAMICS

• 5.1. Outsourcing Dynamics
• 5.2. Survey of Chemists and Managers Active in Medicinal Chemistry
  • Survey Conclusions

Chapter 6 CONCLUSIONS AND FUTURE TRENDS

• 6.1. Optimizing the Interplay of Chemistry and Biology
• 6.2. Effects of the �gIndustrialization�h of Drug Discovery

Chapter 7 EXPERT INTERVIEWS

• 7.1. Christopher Lipinski, PhD
  • Drug Discovery Consultant, Retired Senior Research Fellow, Pfizer
• 7.2. Celerino Abad-Zapatero, PhD
  • Adjunct Professor, University of Illinois at Chicago, Center for Pharmaceutical Biotechnology
• 7.3. Medicinal Chemistry Executive
  • Anonymous; Veteran from Big Pharma
• 7.4. Gilbert Rishton, PhD
  • Founder and Director, Alzheimer' s Institute, California State University Channel Islands
• 7.5. Steven Muskal, PhD
  • CEO, Eidogen-Sertanty
• 7.6. Informatics Chemist
  • Anonymous; Big Pharma
• 7.7. Sidney Topiol, PhD
  • Associate Director, Computational Chemistry, Lundbeck Research

References

• Company Index with Web Addresses